Get the Stockscreener App
1.24
1.59%
-0.02
Opko Health Inc stock is traded at $1.24, with a volume of 3.68M.
It is down -1.59% in the last 24 hours and down -16.78% over the past month.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
See More
Previous Close:
$1.26
Open:
$1.26
24h Volume:
3.68M
Relative Volume:
0.85
Market Cap:
$1.10B
Revenue:
$711.41M
Net Income/Loss:
$-133.73M
P/E Ratio:
-6.5263
EPS:
-0.19
Net Cash Flow:
$-199.99M
1W Performance:
-10.47%
1M Performance:
-16.78%
6M Performance:
-18.42%
1Y Performance:
-1.59%
1-Day Range:
$1.21
$1.2799
1-Week Range:
$1.21
$1.41
52-Week Range:
$1.19
$2.035
Opko Health Inc Stock (OPK) Company Profile
Name
Opko Health Inc
Sector
Industry
Phone
305-575-4181
Address
4400 BISCAYNE BLVD., MIAMI, FL
Compare OPK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.24 | 1.10B | 711.41M | -133.73M | -199.99M | -0.19 |
|
TMO
Thermo Fisher Scientific Inc
|
403.13 | 159.89B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.73 | 142.45B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
491.70 | 37.95B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
106.93 | 30.97B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
148.99 | 26.72B | 15.50B | 1.33B | 2.16B | 7.34 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-25 | Initiated | JP Morgan | Neutral |
| Jun-29-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Jan-24-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-21-21 | Initiated | Ladenburg Thalmann | Buy |
| Nov-25-19 | Initiated | Piper Jaffray | Overweight |
| Mar-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-14-17 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-21-16 | Reiterated | Standpoint Research | Buy |
| Jun-03-16 | Initiated | Standpoint Research | Buy |
| Mar-31-16 | Reiterated | Barrington Research | Outperform |
| Oct-16-15 | Initiated | JP Morgan | Overweight |
| Sep-11-15 | Downgrade | Jefferies | Buy → Hold |
| Mar-03-15 | Downgrade | Oppenheimer | Outperform → Perform |
| May-12-14 | Reiterated | Oppenheimer | Outperform |
| Mar-14-14 | Initiated | Oppenheimer | Outperform |
| Nov-13-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-30-13 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-22-12 | Initiated | Barrington Research | Outperform |
| Dec-01-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jul-14-11 | Initiated | Ladenburg Thalmann | Buy |
View All
Opko Health Inc Stock (OPK) Latest News
Q2 Earnings Forecast for OPKO Health Issued By HC Wainwright - MarketBeat
Entera Bio Announces First Quarter 2025 Financial Results and Business Updates - The Manila Times
Clinical Laboratory Tests Market Top PlayersARUP - openPR.com
Renaissance Technologies LLC Cuts Stake in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Secondary Hyperparathyroidism Treatment Market Grows with Rising CKD Cases | Amgen, Sanofi, OPKO Health - openPR.com
Barclays PLC Increases Holdings in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Opko health outlines $675M-$685M revenue guidance for 2025 amid strategic initiatives - MSN
Voya Investment Management LLC Has $1.85 Million Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Marshall Wace LLP Has $1.36 Million Position in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Invesco Ltd. Has $2.29 Million Stake in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Piper Sandler Keeps Their Buy Rating on Opko Health (OPK) - The Globe and Mail
OPKO Health, Inc. (NASDAQ:OPK) Q1 2025 Earnings Call Transcript - Insider Monkey
Weekly CEO Buys Highlight - GuruFocus
Labcorp Holdings Inc, BioReference Health, OPKO Health, Inc. - Olean Times Herald
OPKO Health, Inc. (NASDAQ:OPK) Short Interest Update - MarketBeat
OPKO Health’s Earnings Call: Mixed Sentiments and Strategic Moves - TipRanks
OPK Stock Slips Following Q1 Earnings Miss, Gross Margin Expands - Yahoo Finance
Quote - OPKO Health, Inc.
OPKO Health Inc (OPK) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ... By GuruFocus - Investing.com Canada
OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt - simplywall.st
OPKO Health Inc (OPK) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ... - Yahoo Finance
Earnings call transcript: Opko Health misses Q1 2025 earnings forecast By Investing.com - Investing.com South Africa
OPKO Health Reports Q1 2025 Financial Highlights - TipRanks
OPKO Health: Q1 Earnings Snapshot - MySA
OPKO Health Inc Q1 2025 Earnings: EPS Misses at -$0.10, Revenue Falls Short at $149.9 Million - GuruFocus
OPKO Health (OPK) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Earnings call transcript: Opko Health misses Q1 2025 earnings forecast - Investing.com
Opko Health earnings missed by $0.01, revenue fell short of estimates - Investing.com
OPKO Health Inc reports results for the quarter ended March 31Earnings Summary - TradingView
OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results - GlobeNewswire
OPKO Health Q1: $225M Oncology Asset Sale to Labcorp Plus New Oral GLP-1 Program Launch - Stock Titan
OPKO Health (NASDAQ:OPK) Now Covered by Analysts at JPMorgan Chase & Co. - MarketBeat
OPKO Health (OPK) to Release Earnings on Wednesday - MarketBeat
Pediatric Growth Hormone Deficiency Treatment Market Size - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
JP Morgan Initiates Coverage of OPKO Health (OPK) with Neutral Recommendation - MSN
Analyst Expectations For OPKO Health's Future - Benzinga
JPMorgan starts Opko Health stock with Neutral rating By Investing.com - Investing.com India
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Benzinga
JPMorgan Initiates OPKO Health at Neutral - marketscreener.com
Opko Health Inc Stock (OPK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Opko Health Inc Stock (OPK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | CEO & Chairman |
Apr 08 '25 |
Buy |
1.48 |
125,000 |
184,650 |
213,876,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Apr 01 '25 |
Buy |
1.65 |
100,000 |
164,850 |
213,751,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Mar 28 '25 |
Buy |
1.70 |
150,000 |
254,385 |
213,651,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Mar 17 '25 |
Buy |
1.74 |
200,000 |
347,820 |
213,501,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Feb 28 '25 |
Buy |
1.71 |
67,434 |
115,312 |
213,301,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 28 '25 |
Buy |
1.47 |
47,537 |
70,060 |
213,234,014 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 17 '25 |
Buy |
1.47 |
150,000 |
220,425 |
213,186,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 15 '25 |
Buy |
1.48 |
500,000 |
740,850 |
213,036,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Dec 13 '24 |
Buy |
1.59 |
125,000 |
199,375 |
212,536,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Dec 11 '24 |
Buy |
1.56 |
500,000 |
781,050 |
212,411,477 |
0.60%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):